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NeurodegenerationStriatal neurons are vulnerable to Huntington's disease (HD). Decreased levels of acetylated alpha-tubulin and
impaired mitochondrial dynamics, such as reduced motility and excessive ﬁssion, are associated with HD; how-
ever, it remains unclear whether and how these factors might contribute to the preferential degeneration of
striatal neurons. Inhibition of the alpha-tubulin deacetylase HDAC6 has been proposed as a therapeutic strategy
for HD, but remains controversial— studies in neurons show improved intracellular transport, whereas studies in
cell-lines suggest it may impair autophagosome–lysosome fusion, and reduce clearance of mutant huntingtin
(mHtt) and damaged mitochondria (mitophagy). Using primary cultures of rat striatal and cortical neurons,
we show thatmitochondria are intrinsically less motile andmore balanced towards ﬁssion in striatal than in cor-
tical neurons. Pharmacological inhibition of the HDAC6 deacetylase activity with tubastatin A (TBA) increased
acetylated alpha-tubulin levels, and induced mitochondrial motility and fusion in striatal neurons to levels ob-
served in cortical neurons. Importantly, TBA did not block neuronal autophagosome–lysosome fusion, and did
not change mitochondrial DNA levels, suggesting no impairment in autophagy or mitochondrial clearance. In-
stead, TBA increased autophagic ﬂux and reduced diffuse mHtt in striatal neurons, possibly by promoting trans-
port of initiation factors to sites of autophagosomal biogenesis. This study identiﬁes the pharmacological
inhibition of HDAC6 deacetylase activity as a potential strategy to reduce the vulnerability of striatal neurons
to HD.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Huntington's disease (HD) is a fatal neurodegenerative disorder
caused by polyglutamine (polyQ) expansion mutations in the huntingtin
protein. Although ubiquitously expressed, mutant huntingtin (mHtt) in-
duces selective neurodegeneration that is most harmful to striatal neu-
rons [1]. There are several reports suggesting that mHtt can induce
mitochondrial dysfunction [2–5], but it is not clear how that might con-
tribute to preferential striatal neurodegeneration. One hypothesis is that
striatal neurons are intrinsically vulnerable tomitochondrial dysfunction.
Indeed, evenwithoutmHtt, striatal neurons show increased susceptibility
to defects of oxidative phosphorylation [6], and to calcium-induced
mitochondrial permeability transition [7] when compared to cortical
neurons.
Abnormal mitochondrial dynamics including excessive mitochon-
drial fragmentation have been suggested to occur as early events in
several neurodegenerative disorders, including HD [8,9]. A betterrsity of Porto, Rua Jorge Viterbounderstanding ofmitochondrial ﬁssion and fusion, and of the regulatory
factors involved, may lead to improved treatments and cures for these
diseases. One open question is whether striatal and cortical neurons
present intrinsic differences in their mitochondrial dynamics proﬁle
thatmay contribute to their differential vulnerability inHD. Concurrent-
ly, one notable challenge is to identify pharmacological strategies to
counteract excessive mitochondrial fragmentation in HD [4,10].
HDAC6 is a cytosolic histone deacetylase presenting α-tubulin
deacetylase and ubiquitin-binding activities [11]. HDAC6 inhibition
was proposed as a therapeutic strategy for HD following evidence
that it compensates intracellular transport deﬁcits in HD models by
increasing alpha-tubulin acetylation levels, which are decreased in
HD patient brains [12,13]. However, targeting HDAC6 in HD is con-
troversial since studies in cell lines suggest that HDAC6 is necessary
for autophagosome–lysosome fusion [14], and also that HDAC6 me-
diates the clearance of mHtt [15] and damaged mitochondria [16],
thereby predicting detrimental effects for HDAC6 inhibition in HD.
Still, this prediction contrasts with data showing no evidence of brain
abnormalities in HDAC6-knockout mice [17,18], thus failing to support
a role for HDAC6 in autophagosome–lysosome fusion, which would be
expected to impair autophagy and cause neurodegeneration [19]. It is
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tion affects neuronal autophagy, and also the clearance of mitochondria
and mHtt in neurons.
Primary cultures of striatal and cortical neurons are frequently used
as an experimentalmodel to explore the differential vulnerability in HD
[7,20]. Here we used ﬂuorescence live-imaging and molecular tech-
niques to investigate whether these neuronal populations present in-
trinsic differences in mitochondrial motility and ﬁssion–fusion
dynamics, andwhether such dynamics aremodulated byHDAC6 inhibi-
tion.We also investigatewhether pharmacological HDAC6 inhibition af-
fects neuronal autophagosome–lysosome fusion, and how it impacts
autophagic ﬂux, mitochondrial levels, and the proteostasis of wild-
type and mutant huntingtin in striatal and cortical neurons.
2. Materials and methods
2.1. Plasmids and antibodies
Plasmids: mito-DsRed2 (mtDsRed;Michael Ryan, La Trobe Universi-
ty, Australia), mCherry-EGFP-LC3B (Jayanta Debnath, University of
California, USA — Addgene 22418 [21]), EGFP-Httex1Q23 and EGFP-
Httex1Q74 (David Rubinsztein, University of Cambridge, UK— Addgene
40261 and 40262 [22]), and pmaxGFP (GFP; Amaxa). Primary antibod-
ies and dilutions for Western blotting: anti-acetylated-histone-H3K9
(ab10812; 1:500), anti-acetylated-α-tubulin [6-11B-1] (ab24610;
1:5000), anti-β-actin [mAbcam 8226] (ab8226; 1:2000), anti-Fis1
(ab71498; 1:250), anti-HDAC6 (ab82557; 1:1000), anti-mitofusin2
[NIAR164] (ab124773; 1:1000), anti-succinate dehydrogenase complex
subunit A [2E3GC12FB2AE2] (SDHA; ab14715; 1:1000) were from
Abcam; anti-α-tubulin [11H10] (#2125; 1:1000), anti-histone-H3
[96C10] (#3638; 1:1000), anti-LC3A/B (#4108; 1:1000) and anti-
SQSTM1/p62 (#5114; 1:500) were from Cell Signaling; anti-OPA1
(612606; 1:1000) was from BD Biosciences; anti-acetylated-cortactin
(09-881, 1:400) was from Merck-Millipore.
2.2. Drugs and reagents
The HDAC6 inhibitor tubastatin A (TBA) (Selleck Chemicals) was
dissolved in dimethyl sulfoxide (DMSO), present at 0.1% in all treatment
and control conditions (‘solvent’). With the proviso that studies in cells
typically require higher concentrations, studies in isolated HDAC iso-
forms suggest that TBA is HDAC6 selective — isolated enzyme IC50
values are 15 nM for HDAC6 and over 1000-fold higher for other
HDAC isoforms, except for HDAC8 which is 60-fold higher [23]. Here
we use TBA always at 1 μM, as previously described for neurons [24,
25]. TBA treatment efﬁcacy is shown in Supplementary Figs. 1 and 2E.
Fura-2 AM, MitoTracker Green FM and cell culture reagents were from
Invitrogen. All other reagents were from Sigma-Aldrich, unless other-
wise stated.
2.3. Neuronal culture and transfection
Sister cortical and striatal primary cultures were generated from
Wistar rat embryos as previously described [7,26], in full compliance
with European Union directive 2010/63/EU. Cortical and striatal cells
were plated at 103 cells permm2 on polyethylenimine coated glass cov-
erslips and maintained in culture medium (Neurobasal supplemented
with 2% B27, 1% fetal bovine serum, 1% penicillin/streptomycin and 1%
GlutaMAX) at 37 °C, 5% CO2. Cytosine arabinoside (10 μM) was added
48 h after plating to prevent glial proliferation. For neuronal transfec-
tion, culture mediumwas replaced with a mixture of 450 μl Neurobasal
(with 1% Glutamax) and 50 μl Opti-MEM (containing 0.3–0.5 μg DNA,
0.5 μl Lipofectamine LTX and 0.5 μl Plus Reagent; Invitrogen). Following
30–45min incubation (37 °C, 5% CO2) neuronswere washed twicewith
Dulbecco's modiﬁed Eagle medium prior to restoring the conditioned
culture medium. The average transfection efﬁciency was 5%, allowingsingle neuron identiﬁcation for analyzing neurites, mitochondria, LC3-
vesicles, or mHtt levels, without excessive overlap between cells.
2.4. Neurite morphology, mitochondrial occupancy, size and number
Neurons with 10 days in vitro (DIV) were ﬁxed (4% paraformalde-
hyde, 37 °C for 15 min) after 24 h transfection with GFP and mtDsRed,
and imaged with an inverted Eclipse TE300 microscope system
(Nikon; 60× PlanFluor 0.85 NA air objective; Polychrome II monochro-
mator, TILL Photonics; C6790 CCD camera and Aquacosmos 2.5 soft-
ware, Hamamatsu). Sholl analysis ([27]; ImageJ) with 1 μm-spaced
concentric circles was performed on binary images (following back-
ground correction and thresholding), to calculate neurite branching
peaks (intersection maxima), outgrowth (summed intersections), and
mitochondrial fractional occupancy (mitochondrial intersections divid-
ed by neuritic intersections). Particle analysis (ImageJ) was used to cal-
culate mitochondrial number and size (Feret diameter) in neurons
divided into ‘mitochondrial regions’, each comprising the area between
two circles of increasing radii: α-region (15–30 μm); β-region
(30–80 μm); γ-region (80–130 μm).
2.5. Mitochondrial motility
Neurons at 10 DIV were loaded with Fura-2 AM (4 μM; for labeling
neurites; 380 nm excitation) and MitoTracker Green (50 nM; for label-
ing mitochondria; 488 nm excitation [28]) for 30 min, washed twice
and live imaged (5 s intervals for 10 min) in recording media
(133 mM NaCl, 5 mM KCl, 1.3 mM CaCl2, 1 mM MgCl2, 1 mM Na2SO4,
0.4 mM KH2PO4, 15 mM glucose, 20 mM HEPES, pH 7.4) at 37 °C. The
proportion of motile mitochondria was assessed via kymographs (20
representative lines per video; Multi Kymograph — J. Rietdorf and A.
Seitz).
2.6. Mitochondrial DNA (mtDNA) levels
Total DNA was extracted with DNeasy Blood & Tissue Kit (Qiagen)
and qPCR was performed with iQ5 System (Bio-Rad) using iQ SYBR
Green Supermix (Bio-Rad). Primers formtDNA (MTND1 gene): forward
5′-AATACGCCGCAGGACCATTC, reverse 5′-GGGGTAGGATGCTCGGATTC.
Primers for nuclear DNA (nDNA; eEF1A gene): forward 5′-AGCCAAGT
GCTAATGTAAGTGAC, reverse 5′-CCCTTGAACCACGGCATCTA. Relative
quantiﬁcations were performed with the Pfafﬂmethod (correcting for
measured efﬁciencies) [29].
2.7. Western blotting
Neuronswere rinsed with ice-cold phosphate-buffered saline (PBS),
lysed in buffer containing 150 mM NaCl, 0.5% deoxycholate, 0.1% SDS,
1% Triton X-100, 50 mM Tris (pH 8.0), and protease inhibitors. Protein
was quantiﬁed by Bradford assay (Bio-Rad). Samples were boiled in
Laemmli buffer, loaded at 20–25 μg per lane in polyacrylamide gels,
electrophoresed under reducing conditions, and electroblotted to
polyvinylidene diﬂuoride membranes (PVDF; Millipore). Membranes
were blocked in PBS with 0.05% Tween 20 (PBST) containing 5% non-
fat dry milk, then incubated overnight at 4 °C with primary antibodies
(diluted in PBST with 5% BSA — bovine serum albumin), followed by
washing in PBST and incubationwith respective horseradish peroxidase
conjugated antibodies for detection by enhanced chemiluminescence.
2.8. Immunoﬂuorescence
Neurons were ﬁxed with 4% paraformaldehyde for 15 min at 37 °C,
washed 3 times in PBS, permeabilized and blocked with 0.1% Triton X-
100 and 3% BSA in PBS (Abdil) for 30min. Neuronswere then incubated
for 1 h with primary antibody (anti-acetylated-cortactin, 1:150 in
Abdil), and washed 3 times with 0.1% Triton X-100 in PBS, followed by
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(Invitrogen; A-11034; 1:200 in Abdil). After assembly in ﬂuorescent
mounting medium (Dako), neurons were imaged with the aforemen-
tioned Eclipse TE300 system, ensuring non-saturating identical equip-
ment settings for intensity comparisons between treatments.
2.9. LC3-vesicle dynamics
Neurons expressing mCherry-EGFP-LC3B were live imaged at
8–10 DIV (48 h post-transfection) in culture media at 37 °C, 5% CO2,
using an Axiovert 200 M, with LSM510 and a 63× Plan-Apochromat
1.4 NA oil objective (Zeiss). Combining acid-sensitive EGFP (488 nm
excitation) with acid-insensitive mCherry (543 nm excitation) allows
distinction of autophagosomes (EGFP + mCherry signal) from
autolysosomes (mCherry signal only) [30]. LC3-positive vesicles were
counted in whole somata Ζ-stacks. Cytoplasmic volume was measured
with 3D Objects Counter (F. Cordelières), deleting nuclei and using dif-
fuse EGFP-LC3 ﬂuorescence to deﬁne somatic boundaries. Vesiclemotil-
ity parameters were analyzed with MTrackJ in 10 min videos at 3 s
intervals, acquiring on the mCherry channel only (minimum velocity
threshold was 0.1 μm/s; [31]). Vesicles crossing the ﬁrst axonal branch
towards the somawere expressed as events per 5min (retrograde ﬂux).
2.10. Huntingtin proteostasis
Neurons were transfected either with ‘wild-type’ Htt (wtHtt; Q23)
or mHtt (Q74) encoding plasmids at 5 DIV [20], and live imaged at 24
and 48 h post-transfection in culture medium at 37 °C, 5% CO2. Fluores-
cently tagged wtHtt exon 1 (EGFP-Httex1Q23) and mHtt exon 1 (EGFP-
Httex1Q74) were excited at 488 nm and imaged with an inverted
ﬂuorescence microscope equipped with a 20× air objective, ensuring
non-saturating identical equipment settings for ﬂuorescence intensity
comparisons. After imaging at 24 h post-transfection (6 DIV), neurons
were treated with either solvent or TBA and re-imaged 24 h later (7
DIV; 48 h post-transfection). Transfected neurons were screened for
the presence of aggregates and their location (soma and neurites), and
their counts expressed in percentage of EGFP-positive neurons. Diffuse
levels of wtHtt or mHtt were measured by the average somatic EGFP
ﬂuorescence in neurons without visible aggregates.
2.11. Image processing and data analysis
Image processing was performedwith ImageJ (http://rsbweb.nih.
gov/ij/; National Institutes of Health) using the indicated plugins.
Numerical data calculations were automated in Excel spreadsheets
(Microsoft). Other data analyses and statistical calculations were
performed using Prism 6.0 (GraphPad Software). Two-tailed
Student's t test was used when comparing two groups, one-way
ANOVAs with Dunnet's post-hoc when comparing three or more
groups, and two-way ANOVA with Sidák's post-hoc when testing
the interaction plus the main effects of region (cortical × striatal)
and treatment (solvent × drugs). Curve ﬁt comparisons in nonlinear
regression analyses were performed with extra sum-of-squares F
test. Unless otherwise stated, data are mean± SEM of the n speciﬁed
in ﬁgure legends.
3. Results
3.1. Mitochondria in striatal neurons are less motile and more balanced
towards ﬁssion than mitochondria in cortical neurons
Neurons are highly polarized post-mitotic cells that distribute their
mitochondria throughout neurites [32]. To investigate whether mito-
chondrial dynamics differ between striatal and cortical neurons, we
started by comparing neurite morphology and relative mitochondrial
levels in 10 DIV cultures. Cortical neurons were more branched thanstriatal neurons, but the average neurite outgrowth of the two popula-
tions was similar (Fig. 1A,B — white bars). The proportion of neurite
length occupied by mitochondria was not signiﬁcantly different in
striatal and cortical neurons (Fig. 1Ci). Together with similar mtDNA/
nDNA ratios (Fig. 1D), these results show that under our experimental
conditions cortical and striatal neurons present identical mitochondrial
levels.
To compare the mitochondrial ﬁssion–fusion balance, we measured
mitochondrial size and number in three concentric ‘mitochondrial re-
gions’ progressively away from soma (α-, β-, and γ-regions; Fig. 2A),
and found thatmitochondrial size was signiﬁcantly affected by distance
from soma, decreasing from the α- towards the γ-region (Fig. 2B). We
also detected that mitochondria in striatal neurons were signiﬁcantly
smaller, but more numerous than in cortical neurons (Fig. 2B,C –
white bars). These data, together with identical mitochondrial levels
(Fig. 1C,D) and higher expression of the ﬁssion-associated Fis1 protein
in striatal neurons (Fis1/SDHA, Table 1; Supplementary Fig. 2), indicate
that the striatal mitochondrial population is intrinsically more balanced
towards ﬁssion. Moreover, when we compared mitochondrial motility,
we found that mitochondria were less motile in striatal than cortical
neurons (Fig. 2D), and that this correlated with decreased α-tubulin
acetylation in the striatal population (Fig. 2E). Signiﬁcantly, we detected
higher expression of the α-tubulin deacetylase HDAC6 in striatal neu-
rons (Fig. 2F), which could explain why striatal neurons present lower
α-tubulin acetylation, and account for their reducedmitochondrial mo-
tility. Indeed,α-tubulin acetylation has been directly correlatedwith re-
cruitment of motor proteins, thereby promotingmicrotubule-mediated
transport [12,33]. Given that increasingmitochondrialmotility likely in-
creases mitochondria contact and fusion-probability, we next tested
whether increasing α-tubulin acetylation by HDAC6 inhibition could
modulate the mitochondrial ﬁssion–fusion balance in neurons.
3.2. HDAC6 inhibition increasesmitochondrial motility and promotesmito-
chondrial fusion in striatal neurons
To assess the effects of HDAC6 inhibition on mitochondrial dynam-
ics, we treated neurons with 1 μMTBA (treatment efﬁcacy and selectiv-
ity was conﬁrmed by detecting increased acetylation of the HDAC6-
substrate α-tubulin-K40, without off-target increases in histone-
H3K9; Fig. 2E; Supplementary Fig. 1). Treatment with TBA signiﬁcantly
increased the proportion of motile mitochondria in cortical and striatal
neurons (Fig. 2D), withoutmodifyingmitochondrial levels (Fig. 1C,D) or
the expression of ﬁssion–fusion proteins (Table 1; Supplementary
Fig. 2). In cortical neurons, TBAhad no signiﬁcant effect onmitochondri-
al size and number (Fig. 2B,C). In striatal neurons, however, TBA in-
creased the size and reduced the number of mitochondria (Fig. 2B,C).
These results indicate that by increasing the lowmitochondrial motility
of striatal neurons, TBA treatment promotes mitochondrial contact and
fusion, thereby modulating their ﬁssion–fusion balance.
Previous studies with HDAC6-deﬁcient cell lines implicated HDAC6
in mitochondrial clearance [16] and in autophagosome–lysosome
fusion [14]. However, our present ﬁndings show that pharmacological
HDAC6 inhibition with TBA increases α-tubulin acetylation without
altering mitochondrial levels (Fig. 1C,D), suggesting unaltered mito-
chondrial clearance in neurons. Moreover, HDAC6-knockout mice
show no signiﬁcant neuropathology [17,18], which challenges the
role of HDAC6 in neuronal autophagosome–lysosome fusion, a cru-
cial process for neuronal homeostasis [19]. Therefore, we next inves-
tigated how pharmacological HDAC6 inhibition with TBA impacts
autophagosome–lysosome fusion in live neurons.
3.3. HDAC6 inhibition does not block neuronal autophagosome–lysosome
fusion, but instead increases autophagic ﬂux
To investigate the effects of HDAC6 inhibition on neuronal
autophagosome–lysosome fusion, we imaged live neurons expressing
Fig. 1.Mitochondrial fractional occupancy and mtDNA levels in cortical and striatal neurons. (A–D). Cortical and striatal neurons following treatment with solvent or 1 μM TBA for 72 h.
(A) Intersections with neurites (top) or mitochondria (bottom) as a function of distance from soma (Sholl analysis with log-normal curve ﬁts); (B) (i) Neurite branching peak and (ii)
outgrowth; (C) mitochondrial fractional occupancy with distance from soma (one-phase decay curve ﬁt); n = 11–17 neurons from 3 independent cultures, per treatment condition.
(D)Mitochondrial DNA levels relative to nuclear DNA; n=3 independent cultures. n.s., not signiﬁcant (p N 0.05); *p b 0.05, to solvent-treated cortical neurons; #p b 0.05 to solvent-treated
striatal neurons.
2487P. Guedes-Dias et al. / Biochimica et Biophysica Acta 1852 (2015) 2484–2493mCherry-EGFP-LC3. Under control conditions (solvent), the vast major-
ity of somatodendritic LC3-vesicles were autolysosomes (acidiﬁed,
with loss of EGFP-ﬂuorescence; Fig. 3Ai), indicating that constitutiveFig. 2.Mitochondrial dynamics andHDAC6 levels in cortical and striatal neurons. (A) Representa
showmitochondria (mtDsRed) and neurites (GFP) with 10 μm scale bars. (B, C)Mitochondrial
vent or 1 μMTBA for 72 h. Black triangles denote signiﬁcant effects of region (α towards γ) onm
cultures, per treatment condition. (D) Mitochondrial motility and representative kymograph; n
condition in each culture). (E, F) Representative immunoblots and quantiﬁcation of acetylatedα
24h;n=4 independent cultures. Region p values are from two-wayANOVAS; n.s., not signiﬁcan
solvent-treated striatal neurons.autophagosome–lysosome fusion is highly efﬁcient in neurons [34]. In-
hibition of the lysosomal proton pump with baﬁlomycin A1 (BAF) im-
paired LC3-vesicle acidiﬁcation (EGFP ﬂuorescence retained; Fig. 3Aiii)tive neuron divided in encircled ‘mitochondrial regions’α, β, γ, and respective radii. Insets
size and number quantiﬁcation within theα, β, and γ regions of neurons treated with sol-
itochondrial size (p b 0.05, ANOVA linear trend); n=15–21 neurons from 3 independent
= 3–10 independent cultures (296–417 individual mitochondria analyzed per treatment
-tubulin levels (E) and of HDAC6 levels (F) in neurons treatedwith solvent or 1 μMTBA for





Fis1/SDHA ↑ 1.35 ± 0.07, p b 0.01 0.85 ± 0.11, p= 0.23 0.91 ± 0.13, p= 0.46
OPA1/SDHA 1.11 ± 0.04, p= 0.07 0.97 ± 0.08, p= 0.66 0.96 ± 0.17, p= 0.64
Mfn2/SDHA 1.11 ± 0.07, p= 0.20 1.03 ± 0.11, p= 0.87 1.05 ± 0.07, p= 0.48
Quantiﬁcation of protein levels by immunoblot densitometry. Data are mean ± SEM of the ratios to solvent; n= 3–7 independent cultures; p b 0.05, ratio paired t test. Arrows indicate
direction of differences.
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predicted for impaired autophagosome–lysosome fusion [34]. Treat-
ment with TBA increased α-tubulin acetylation (Fig. 2E) without
impairing LC3-vesicle acidiﬁcation (Fig. 3Aiv,v) or p62 digestion
(Fig. 3B, Table 2). These results show that TBA inhibits HDAC6-
mediated α-tubulin deacetylation without blocking neuronal
autophagosome–lysosome fusion.
Cortactin deacetylation by HDAC6was found necessary for constitu-
tive autophagosome–lysosome fusion in ﬁbroblasts. We therefore test-
ed if TBA modiﬁed cortactin acetylation in neurons. Under control
conditions, in situ acetyl-cortactin immunoreactivity was primarily de-
tected in proximal neurites (Fig. 3C), with some cortical and striatal
neurons showing nuclear immunoreactivity, as previously reported for
hippocampal neurons [35]. Treatment with TBA increased neuronal
acetyl-cortactin immunoreactivity in situ (Fig. 3C), although this was
not conﬁrmed by immunoblotting (Fig. 3D). The function of acetyl-
cortactin in neurons is mostly unknown [35]; however, given that
cortactin is scarce throughout the axons [36,37] – where most
autophagosome-fusion events occur [38,39] – cortactinmay not be crit-
ical for such events in neurons.
To investigate whether HDAC6 inhibition and the resulting in-
crease in α-tubulin acetylation modiﬁed the dynamics of neuronal
LC3-vesicles, we monitored the direction and velocity of LC3-
vesicles in distal axons (N400 μm from soma), the retrograde LC3-
vesicle ﬂux through the ﬁrst axonal branch (a critical converging
point for vesicles moving towards the soma), and we also quantiﬁed
somatic autolysosomes (Fig. 4). Under control conditions, most LC3-Fig. 3. Neuronal autophagosome-lysosome fusion and autophagy markers. (A) Representative
cated treatments: RAP— 10 nM rapamycin, BAF— 25 nM baﬁlomycin A1, TBA— 1 μM tubastati
RAP for 24 h before protein extraction; BAF was present only for the last 6 h of incubation (se
cortactin in cortical neurons treated with solvent or TBA for 24 h. (D) Immunoblot for acetyl-cvesicles in distal axons were autophagosomes (mCherry- and EGFP-
positive; Fig. 4A) and exhibited robust retrograde movement
(Fig. 4B,C), as previously described [31,38]. Treatment with TBA
modiﬁed neither LC3-vesicle direction (Fig. 4C) nor velocity
(Fig. 4C,D), but signiﬁcantly increased the retrograde ﬂux through
the ﬁrst axonal branch (Fig. 4E,F), and the number of somatic
autolysosomes (Fig. 4G,H), suggesting that more autophagosomes
are being formed and converted into autolysosomes while moving
towards the soma. TBA treatment also increased LC3-II expression,
while decreasing p62 levels (Fig. 3B, Table 2), as predicted for in-
creased formation of autophagosomes together with enhanced lyso-
somal digestion [34], indicating that TBA increases autophagic ﬂux.
Given the evidence that huntingtin proteostasis is regulated by au-
tophagy [20], we therefore investigated whether TBA treatment
could modulate huntingtin proteostasis in cortical and striatal
neurons.
3.4. The HDAC6 inhibitor TBA promotes clearance of diffuse mHtt in striatal
neurons
We compared huntingtin proteostasis in cortical and striatal
neurons expressing either an EGFP-wtHtt construct with 23Q (‘wild-
type’) or an EGFP-mHtt construct with 74Q (‘mutant’), which were im-
aged at 24 h and 48 h post-transfection (Fig. 5A). Neurons expressing
wtHtt presented a diffuse pattern of EGFP distribution (Fig. 6A), with
no visible aggregates at any imaging timepoint (Fig. 5A). In contrast,
neurons expressing mHtt presented more diverse EGFP distributionsomata of cortical neurons expressing mCherry-EGFP-LC3, imaged live following the indi-
n A. (B) Immunoblot for autophagymarkers: neurons were incubatedwith solvent, TBA or
e Table 2 for quantiﬁcations). (C) Representative immunoﬂuorescence images of acetyl-
ortactin with respective quantiﬁcation relative to β-actin; n= 4 independent cultures.
Table 2
Autophagy markers in cortical and striatal neurons.
LC3-II/β-actin p62/β-actin
Cortical Striatal Cortical Striatal
TBA/solvent ↑ 1.48 ± 0.10, p b 0.05 ↑ 1.25 ± 0.04, p b 0.01 0.88 ± 0.20, p= 0.52 ↓ 0.82 ± 0.02, p b 0.05
BAF/solvent ↑ 1.79 ± 0.12, p b 0.05 ↑ 2.43 ± 0.21, p b 0.01 ↑ 1.90 ± 0.18, p b 0.05 1.22 ± 0.17, p= 0.34
RAP/solvent 1.18 ± 0.11, p= 0.24 ↑ 1.72 ± 0.17, p b 0.05 0.66 ± 0.13, p= 0.14 ↓ 0.58 ± 0.08, p b 0.05
Quantiﬁcation of protein levels by immunoblot densitometry. Data are mean ± SEM of the ratios to solvent; n= 3–4 independent cultures; p b 0.05, ratio paired t test. Arrows indicate
direction of differences.
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1; Fig. 6Bi), while others presented somatic (Fig. 5B — neuron 2) and/
or neuritic aggregates (Fig. 5B — neuron 3 and box 3′).
The overall proportion of neurons with mHtt aggregates at 24 h
was higher for cortical than for striatal neurons, increasing at identi-
cal rates for both populations towards 48 h (Fig. 5Ci). Within mHtt
aggregate-containing neurons, the proportion with neuritic aggre-
gates at 24 h was similar and increased over time without signiﬁcant
differences between cortical and striatal neurons (Fig. 5Di). In neu-
rons without aggregates, diffuse mHtt levels were higher at 24 h
and decreased over time for cortical neurons, whereas the opposite
patternwas observed for striatal neuronswhere diffusemHtt continued
to increase towards 48 h (Fig. 6Bii). In contrast, diffuse wtHtt levels
showed no signiﬁcant changes over timewithin cortical or striatal neu-
rons (Fig. 6Aii), thus highlighting that the differential proteostasis of dif-
fuse huntingtin is polyQ-dependent. Moreover, these results suggest
that the time-dependent clearance of diffuse mHtt is more efﬁcient in
cortical than striatal neurons (Fig. 6Bii). Given the aforementionedFig. 4. Neuronal LC3-vesicle dynamics. (A) mCherry- and EGFP- positive LC3-vesicles in distal a
tionary (arrow) and moving (arrowhead) LC3-vesicles in a distal axon (only the mCherry chan
treatedwith solvent or TBA (1 μM, 24 h); n=21–26 axonal sections from 20–21 neurons from
rons treated with solvent or TBA; n=92–109 vesicles from 19–20 neurons from 4 independen
the soma. (F) Retrograde ﬂux of LC3-vesicles through theﬁrst axonal branch of cortical neurons
soma showing different number of LC3-vesicles depending on the focal plane (left vs. right). (
stacks imaged after 24 h treatment with solvent, TBA or rapamycin (RAP, 10 nM); n= 13–68data indicating that HDAC6 inhibition increases neuronal autophagic
ﬂux, we investigated whether TBA treatment modulated huntingtin
proteostasis in neurons.
Treatment with the HDAC6 inhibitor TBA did not modify the overall
proportion of cortical or striatal neurons with mHtt aggregates
(Fig. 5Cii), while showing a trend for reducing mHtt aggregates in
striatal neurites (Fig. 5Dii). Moreover, treatment with TBA signiﬁcantly
reduced diffuse mHtt levels in striatal neurons (Fig. 6Biii), but did not
alter those ofwtHtt (Fig. 6Aiii). Thus, pharmacological HDAC6 inhibition
in neurons seems to increase the clearance of diffuse huntingtin in a
polyQ-dependent manner.
4. Discussion
Here we have shown that wild-type striatal and cortical neurons
present intrinsic differences in mitochondrial ﬁssion–fusion and traf-
ﬁcking dynamics. Mitochondria in striatal neurons are more balanced
towards ﬁssion and are less motile than those in cortical neurons.xons of live cortical neurons. (B) Time-lapse (top) and kymograph (bottom) showing sta-
nel is shown). (C) Movement direction of LC3-vesicles in distal axons of cortical neurons
4 independent cultures. (D) Retrograde LC3-vesicle velocity in distal axons of cortical neu-
t cultures. (E) LC3-vesicles (arrowheads) moving through the ﬁrst axonal branch towards
treatedwith solvent or TBA; n=11–14 neurons from 2 independent cultures. (G) Cortical
H) Quantiﬁcation of autolysosomes (mCherry signal only) in cortical neuronal somata Z-
neurons from 2–7 independent cultures. **p b 0.01 vs. solvent. Scale bars: 10 μM.
Fig. 5.Huntingtin proteostasis in cortical and striatal neurons. (A) Schematic experimental design for assessing wtHtt and mHtt proteostasis in cortical and striatal neurons and its mod-
ulation byHDAC6 inhibition. (B) RepresentativemHtt (EGFP-Httex1Q74) expression patterns: (1) diffuse; (2) somatic and (3, 3′) neuritic aggregates. (3′) straightened axonal section to the
right of green box. (C and D) (i) region × time: comparison of solvent-treated cortical and striatal neurons from 24 to 48 h; (ii) region × treatment: comparison of cortical and striatal
neurons at 48 h, following 24 h treatment with solvent or 1 μM TBA. (C) Neurons with mHtt aggregates in percentage of EGFP-positive neurons; (D) Neurons with neuritic aggregates,
in percentage of aggregate-containing neurons; n= 3 independent cultures with 599–852 EGFP-positive neurons per experimental group. Region and time p values are from two-way
ANOVAS.
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balance by increasing mitochondrial motility and promoting fusion.
Pharmacological HDAC6 inhibition with TBA did not block neuronal
autophagosome-lysosome fusion, but increased autophagic ﬂuxFig. 6. Levels of diffuse wild-type and mutant huntingtin in cortical and striatal neurons. Data
(i) Representative neurons expressing diffuse wtHtt (EGFP-Httex1Q23) or mHtt (EGFP-Httex1Q
24 to 48 h; (iii) Region × treatment: comparison of cortical and striatal neurons at 48 h, follow
diffuse wtHtt per experimental group, from 2 independent cultures; (Bii, iii) n=86–220 neuro
action, region, and time p values are from two-way ANOVAS; **p b 0.01 to solvent-treated corand reduced diffuse mHtt in striatal neurons, without changing the
levels of wtHtt. These data provide insight into HD striatal vulnera-
bility and experimental therapeutics with HDAC6 inhibition, as ad-
dressed below.are from neurons expressing only diffuse huntingtin (wtHtt or mHtt) at 24 or 48 h. (A, B)
74); (ii) Region × time: comparison of solvent-treated cortical and striatal neurons from
ing 24 h treatment with solvent or 1 μM TBA; (Aii, iii) n= 133–166 neurons expressing
ns expressing diffuse mHtt per experimental group, from 3–4 independent cultures. Inter-
tical neurons; ##p b 0.01 to solvent-treated striatal neurons.
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ferences in ﬁssion–fusion balance between striatal and cortical neurons
Mitochondrial dysfunction, including impaired calcium handling,
excessive ﬁssion and reduced trafﬁcking, are associated with HD patho-
physiology [2–5]. Previous studies have proposed that excessive mito-
chondrial fragmentation in HD involves the direct interaction between
mHtt and the ﬁssion-mediator Drp1, upregulating its GTPase activi-
ty [40,41]. Importantly, the upregulation of Drp1 GTPase activity was
found stronger in the striatum than in the cortex of BACHD mice [41].
Here we show that mitochondria in wild-type striatal neurons are in-
trinsicallymore balanced towards ﬁssion and present higher expression
levels of the Drp1 receptor Fis1 than cortical neurons. Higher Fis1 levels
may increase the susceptibility of striatal neurons to the upregulation of
Drp1 activity by mHtt and contribute towards striatal neurons being
precociously affected in HD. Additionally, we show that mitochondria
in striatal neurons display lower motility than in cortical neurons.
Such intrinsically lowermotilitymay contribute to themore striking in-
hibition of mitochondrial trafﬁcking by diffusemHtt in striatal [42] than
in cortical neurons [43]. Mechanistically, the higher HDAC6 expression
that we found in striatal than in cortical neurons plausibly explains
the lower α-tubulin acetylation levels and also the reduced motility of
striatal mitochondria.
TBA, the inhibitor of HDAC6, increased tubulin acetylation andmito-
chondrial motility in cortical and striatal neurons, consistent with in-
creased motor afﬁnity to acetylated microtubules [12,33], and with
previous studies in hippocampal [44] or dorsal-root-ganglion neurons
[24]. We also show that TBA shifts themitochondrial ﬁssion–fusion bal-
ance of striatal neurons towards more fusion, possibly because increas-
ingmicrotubule-dependentmovement increases fusion probability [45,
46], particularly when mitochondrial contact probability is otherwise
reduced by lowmotility. Inhibition of mitochondrial ﬁssion is emerging
as a pharmacological strategy to counteract excessivemitochondrialﬁs-
sion in neurodegenerative diseases, such as HD [47,48]. However, sufﬁ-
cient ﬁssion must remain for suitable mitochondrial distribution and
quality-control [49–51]. Since TBA treatment promoted mitochondrial
fusion in striatal neurons, pharmacological inhibition of HDAC6 war-
rants further investigation as a strategy to counteract excessive mito-
chondrial ﬁssion in HD.
4.2. HDAC6 inhibition does not block autophagosome–lysosome fusion in
neurons, but instead stimulates neuronal autophagic ﬂux
Studies using HDAC6-deﬁcient cell lines suggest that the clearance
of damaged mitochondria and misfolded protein aggregates relies on a
common autophagic pathway dependent on HDAC6 [16]. Moreover,
HDAC6 was reported necessary for constitutive autophagosome–
lysosome fusion [14], a crucial step in autophagy. Importantly, the
HDAC6 inhibitor TBAwas designed to selectively inhibit the deacetylase
activity of HDAC6 [23], likely preserving the ubiquitin-binding activity
of HDAC6 that is considered important for detecting damaged mito-
chondria that have been targeted for clearance [16]. Here we show
that pharmacological HDAC6 inhibition with TBA effectively increases
α-tubulin acetylation in neurons, without blocking their LC3-vesicle
acidiﬁcation and p62 digestion, and without modifying their mtDNA/
nDNA levels. Thus, our data suggest that the deacetylase activity of
HDAC6 is dispensable for neuronal autophagosome–lysosome fusion,
and that the preserved ubiquitin-binding activity in the presence of TBA
allows for HDAC6-dependent clearance of ubiquitinated mitochondria.
The present study shows that HDAC6 inhibition induces neuronal
autophagicﬂux. Indeed, the higher LC3-vesicle retrograde ﬂux,more so-
matic autolysosomes, increased LC3-II and decreased p62 levels we
found in TBA-treated neurons, are strongly indicative of increased
autophagosomal biogenesis and efﬁcient autophagic clearance [39]. In
agreement with our ﬁndings, HDAC6 inhibition was recently reported
to induce autophagic ﬂux in primary cardiomyocytes [52] and tofacilitate the autophagic degradation of Aβ and hyperphosphorylated
tau [53].
Acetylated microtubules were reported to allow autophagy stimula-
tion upon nutrient deprivation [54] and to be required for the fusion of
autophagosomes and lysosomes [55]. Increased α-tubulin acetylation
by HDAC6 inhibition may thus facilitate autophagosome–lysosome fu-
sion and autolysosome formation along the axon. But how might
HDAC6 inhibition stimulate autophagosomal biogenesis? We hypothe-
size that the associated increase in microtubule-dependent transport
promotes initiating factor arrival to sites of autophagosomal formation.
Such factors might include the endoplasmic reticulum subdomains
containing DFCP1 (Double-FYVE-Containing-Protein-1; involved in neu-
ronal autophagosomal biogenesis: [39,56]), the c-Jun-N-terminal-
protein-Kinase-1 (JNK1; required for autophagosomal biogenesis: [57]),
and the JNK1-interacting protein (JIP1; required for autophagosomal
exit from distal axons: [58,54]).
4.3. Striatal and cortical neurons differ inmHtt proteostasis, and HDAC6 in-
hibition promotes diffuse mHtt clearance
Here we found higher initial levels of diffuse mHtt and more pro-
nounced aggregation in cortical than striatal neurons, consistent with
higher initial levels predicting aggregate formation [59,60], and with
more aggregates in cortex than striatum in HD patients [61]. In the ab-
sence of aggregates, our data suggest that diffuse mHtt accumulates
over time in striatal but not in cortical neurons, which is consistent
with a longer mean lifetime of mHtt in striatal than cortical neurons
[20], and with recent data showing preferential accumulation of mHtt
in the striatum [62]. The direct correlation of diffuse mHtt levels with
the risk of neuronal death suggests that the toxic species reside within
the diffuse fraction [59,60] and, therefore, that treatments capable of re-
ducing diffuse mHtt should hold neuroprotective potential.
Our data show that theHDAC6 inhibitor TBA reduced diffusemHtt in
striatal neurons. Signiﬁcantly, this effect was speciﬁc for the expanded
polyQ in mHtt (Q74), given that levels of diffuse wtHtt (Q23) remained
unchangedwith TBA treatment.Moreover, TBAdid not alter the propor-
tion of cortical and striatal neurons with mHtt aggregates, suggesting
that the deacetylase activity of HDAC6 is dispensable for aggregate for-
mation and clearance in neurons. These present ﬁndings in neurons ap-
parently contrast with studies in HDAC6-knockout cell-lines showing
reduced clearance of protein aggregates [63] and reduced autophagic
degradation ofmHtt [15]. Our ﬁndings agree, however, with other stud-
ies in neurons, where HDAC6 inhibition alleviated abnormal Aβ and tau
accumulation [53,64], and with in vivo HDAC6-knockout in R6/2 mice
showing no increase in mHtt aggregates [65]. Thus, as previously sug-
gested [65], some of the effects of HDAC6 in cell-lines may not apply
to neurons.
HDAC6-knockout R6/2 mice showed neither symptomatic im-
provement, nor changes in mHtt aggregate load [65]. However, stud-
ies reporting increased mHtt clearance upon induction of autophagy
have most frequently used 68-97Q mHtt [66–70], whereas HDAC6-
knockout R6/2 had an unusually high mHtt polyQ–201Q [65]. More-
over, aggregates precede symptom onset in R6/2 [65], and data from
neuronal models predict that diminishing diffuse mHtt levels should
be more beneﬁcial in the ‘pre-aggregate epoch’ [60]. Furthermore,
although HDAC6-knockout R6/2 mice showed no changes in global
levels of soluble mHtt, their cortex showed decreased soluble mHtt
(no data on soluble mHtt was reported for their striatum; [65]).
Therefore, it would be valuable to start HDAC6 inhibition at the
pre-aggregate epoch and test for delayed symptom onset in HD
mice with shorter polyQ and slower disease progression.
5. Concluding remarks
The intrinsic balance towards ﬁssion and lower motility of striatal
mitochondria may contribute towards the greater sensitivity of striatal
2492 P. Guedes-Dias et al. / Biochimica et Biophysica Acta 1852 (2015) 2484–2493neurons to HD-associated mitochondrial fragmentation and impaired
trafﬁcking. Here we show that pharmacological HDAC6 inhibition
with TBA approximates the mitochondrial ﬁssion–fusion balance and
mitochondrial motility of striatal neurons to that of the less HD-
vulnerable cortical neurons, increases neuronal autophagic ﬂux, and
promotes clearance of diffuse mHtt in striatal neurons. Recent in vivo
studies support HDAC6 inhibition as a neuroprotective strategy in
Alzheimer's disease [18,53], Charcot–Marie–Tooth [24], and amyotro-
phic lateral sclerosis [71]. The present study supports pharmacological
HDAC6 inhibition as a strategy with the potential to reduce striatal vul-
nerability to HD.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.08.012.
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